Veracyte Inc (VCYT)

Return on assets (ROA)

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Net income (ttm) US$ in thousands 26,335 33,049 24,138 -9,268 -54,041 -68,177 -71,997 -47,548 -26,653 -27,783 -36,560 -43,244 -48,650 -48,156 -75,563 -73,079 -63,074 -65,061 -34,909 -34,323
Total assets US$ in thousands 1,344,100 1,315,410 1,300,040 1,275,020 1,234,330 1,200,070 1,137,820 1,124,940 1,161,110 1,157,120 1,156,420 1,125,960 1,144,200 1,173,590 1,187,820 1,186,360 1,027,440 1,025,140 457,163 454,151
ROA 1.96% 2.51% 1.86% -0.73% -4.38% -5.68% -6.33% -4.23% -2.30% -2.40% -3.16% -3.84% -4.25% -4.10% -6.36% -6.16% -6.14% -6.35% -7.64% -7.56%

June 30, 2025 calculation

ROA = Net income (ttm) ÷ Total assets
= $26,335K ÷ $1,344,100K
= 1.96%

The analysis of Veracyte Inc's return on assets (ROA) over the specified periods reveals a trajectory characterized by initial losses, gradual improvement, and subsequent fluctuations. Starting with a negative ROA of -7.56% as of September 30, 2020, the company maintained negative profitability throughout the subsequent periods, with marginal improvements observed over time.

Between September 2020 and March 2022, the ROA showed a decreasing negative trend, reaching approximately -2.40% by March 31, 2023, indicating a reduction in the loss relative to total assets. Notably, the period from September 2023 onward marks a significant shift; the ROA turns positive in December 2024 at +1.86%, with further gains projected into March and June 2025, reaching 2.51% and 1.96%, respectively.

This progression from persistent negative values to positive territory suggests that the company has experienced a meaningful turnaround in its asset efficiency and profitability. The transition indicates improved operational performance, potentially driven by increased revenues, cost management, or a combination thereof.

In summary, Veracyte Inc's ROA demonstrates a trend of gradual recovery from negative performance to positive margins, reflecting enhanced utilization of assets to generate net income during the analyzed period.